Buspirone

Generic Name: Buspirone

Brand Names: Buspar

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₁N_₅O_₂

CAS Number: 36505-84-7

Unique Ingredient Identifier: TK65WKS8HL

Background: Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspiro...

Indication: Indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.

Associated Conditions: Anxiety Disorders, Depression

Associated Therapies: -

Clinical Trials

Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine

Not Applicable

Completed

Conditions: Cocaine Use Disorders

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2012-07-12

Last Posted Date: 2016-02-19

Lead Sponsor: William Stoops

Target Recruit Count: 9

Registration Number: NCT01639157

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States

Buspirone Therapy for Localized Epilepsy

Phase 2

Terminated

Conditions: Anxiety Disorder
Partial Epilepsy
Seizures
Depression
Epilepsy

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2011-12-21

Last Posted Date: 2021-10-05

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 9

Registration Number: NCT01496612

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders

Phase 2

Withdrawn

Conditions: Autism Spectrum Disorder (ASD)

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2011-07-18

Last Posted Date: 2024-06-28

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01395953

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Psychopharmacology for Cocaine Dependence - Buspirone

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Placebo for Buspirone
Drug: Buspirone
Drug: Methylphenidate
Drug: Placebo for Methylphenidate

First Posted Date: 2010-12-28

Last Posted Date: 2017-05-04

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 50

Registration Number: NCT01267292

Locations: 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States

Buspirone Treatment for Marijuana Dependence

Phase 4

Completed

Conditions: Marijuana Dependence

Interventions: Drug: Placebo
Drug: Buspirone

First Posted Date: 2009-04-03

Last Posted Date: 2016-08-10

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 175

Registration Number: NCT00875836

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder

Phase 2

Completed

Conditions: Autistic Disorder

Interventions: Drug: Buspirone
Drug: Placebo

First Posted Date: 2009-04-01

Last Posted Date: 2016-07-26

Lead Sponsor: Chugani, Diane C.

Target Recruit Count: 166

Registration Number: NCT00873509

Locations: 🇺🇸
Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States
🇺🇸
Children's Hospital of Michigan Wayne State University, Detroit, Michigan, United States
🇺🇸
University California Davis M.I.N.D. Institute, Sacramento, California, United States

and more 3 locations

Buspirone as a Potential Treatment for Recurrent Central Apnea

Phase 3

Terminated

Conditions: Central Apnea
Heart Failure

Interventions: Drug: Acetazolamide
Drug: Buspirone

First Posted Date: 2008-09-04

Last Posted Date: 2016-03-14

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 8

Registration Number: NCT00746954

Locations: 🇺🇸
VA Medical Center, Cleveland, Cleveland, Ohio, United States

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

Phase 1

Completed

Conditions: To Determine Bioequivalence Under Fed Conditions

Interventions: Drug: Buspirone HCl
Drug: Buspar

First Posted Date: 2008-04-04

Last Posted Date: 2017-09-26

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 21

Registration Number: NCT00652730

Locations: 🇨🇦
Phoenix International Life Sciences inc, St-Laurent, Quebec, Canada

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: To Determine Bioequivalence Under Fasting Conditions

Interventions: Drug: buspirone HCl
Drug: Buspar

First Posted Date: 2008-04-04

Last Posted Date: 2008-04-04

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 48

Registration Number: NCT00653419

Locations: 🇨🇦
Phoenix International Life Sciences, Inc., St-Laurent, Quebec, Canada

A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence

Phase 2

Completed

Conditions: Marijuana Abuse

First Posted Date: 2006-08-04

Last Posted Date: 2012-01-12

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 81

Registration Number: NCT00360191

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy